Dimensional Fund Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,307,030 shares of the specialty pharmaceutical company's stock after selling 405,311 shares during the quarter. Dimensional Fund Advisors LP owned about 3.97% of Supernus Pharmaceuticals worth $119,239,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in SUPN. Rockefeller Capital Management L.P. increased its position in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock valued at $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth about $49,000. EverSource Wealth Advisors LLC bought a new stake in Supernus Pharmaceuticals in the second quarter worth about $51,000. Hantz Financial Services Inc. raised its position in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $55,000.
Analysts Set New Price Targets
A number of analysts recently commented on SUPN shares. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $62.83.
Check Out Our Latest Report on SUPN
Supernus Pharmaceuticals Stock Up 1.6%
Supernus Pharmaceuticals stock opened at $47.73 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12 month low of $32.83 and a 12 month high of $59.68. The stock has a market cap of $2.77 billion, a P/E ratio of -93.59, a P/E/G ratio of 1.00 and a beta of 0.54. The company's fifty day simple moving average is $46.46 and its 200-day simple moving average is $49.20.
Supernus Pharmaceuticals Company Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Featured Stories
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
